Electrical storm in pregnancy uncovering an arrhythmogenic cardiomyopathy: a case report Authors: Sara Sóñora-López, Víctor González-Fernández, Jaume Francisco-Pascual, Laura Galian-Gay, Antonia Pijuan-Domènech, Valentina Rossi, Alessio Gasperetti, Gregorio Tersalvi, Leo Bergau, Deepti Ranganathan Published: 2026 ABSTRACT AbstractBackgroundPregnancy involves numerous physiological changes in the cardiovascular system to guarantee foetal metabolic demands. In patients with cardiovascular disease, these adaptations can decompensate their underlying condition, leading to maternal and obstetric complications.We report a case of arrhythmogenic cardiomyopathy presenting as an electrical storm during pregnancy, highlighting both diagnostic and management challenges.Case summaryA 35-year-old pregnant woman at 18 weeks of gestation presented with an electrical storm, experiencing multiple episodes of sustained ventricular tachycardia. Diagnostic tests, including a non-contrast cardiac magnetic resonance, were suggestive of biventricular arrhythmogenic cardiomyopathy. After a multidisciplinary team discussion, the patient was treated with antiarrhythmic agents, and an implantable cardioverter-defibrillator was implanted. She was discharged after 10 days, and a delivery plan was made for a scheduled induction at 38 weeks, which proceeded without complications. Genetic testing revealed a desmoplakin (DSP) mutation, further supporting the diagnosis.DiscussionPregnancy can precipitate arrhythmic events, particularly in women with underlying cardiovascular disease. This case illustrates how pregnancy-induced haemodynamic stress may trigger previously undiagnosed cardiomyopathy. Management of such cases requires a multidisciplinary approach, adherence to clinical guidelines, and careful balancing of maternal and foetal risks. The patient’s successful management, including guided antiarrhythmic therapy and device implantation with minimal radiation exposure, highlights the importance of individualized care and the role of a dedicated cardio-obstetrics team.Keywords: Case report, Electrical storm, Ventricular tachycardia, Pregnancy, Arrhythmogenic cardiomyopathy Pregnancy can unmask or exacerbate underlying cardiovascular disease. Electrical storm is a rare but serious complication during pregnancy that requires prompt recognition and management. Pregnancy can unmask or exacerbate underlying cardiovascular disease. Electrical storm is a rare but serious complication during pregnancy that requires prompt recognition and management. Multidisciplinary, guideline-directed care in dedicated cardio-obstetric units is essential to optimize both maternal and foetal outcomes, balancing treatment efficacy with foetal safety. Multidisciplinary, guideline-directed care in dedicated cardio-obstetric units is essential to optimize both maternal and foetal outcomes, balancing treatment efficacy with foetal safety. Introduction Cardiovascular disease (CVD) complicates 1%–4% of pregnancies and is the leading cause of maternal death in high-income countries.1,2 The incidence of cardiovascular adverse events during pregnancy is rising due to older maternal age, higher prevalence of cardiovascular risk factors, and improved survival of women with congenital heart disease. Identifying these high-risk patients is essential for proper risk assessment, prevention, and management.2,3 Given the ethical limitations in pregnancy research, evidence is largely observational. Guideline adherence and referral to tertiary centres with dedicated cardio-obstetric care units become cornerstones of safe management. Understanding the cardiovascular drug risks and safety profiles of diagnostic techniques and procedures is crucial to balancing maternal benefit with foetal safety. Summary figure Illustrative overview of the patient’s clinical course, highlighting key diagnostic findings (including MRI and ECG) and therapeutic interventions, with ICD implantation guided by electroanatomic mapping. ECG: electrocardiogram. ICD: implantable cardioverter-defibrillator. MRI: magnetic resonance imaging. Case presentation A 35-year-old woman, 18 weeks pregnant, was referred to our centre for an electrical storm. She had no medical history and two previous uncomplicated full-term deliveries. The patient was attended by the Emergency Medical Services after suffering a witnessed syncope at home. Upon their arrival, she was alert, with a heart rate of 220 bpm while maintaining normal blood pressure. The electrocardiogram (ECG) showed a monomorphic wide-complex tachycardia with right bundle branch block pattern, superior axis, and late transition in V6 (Figure 1). Ventricular tachycardia (VT) was suspected, and electrical cardioversion successfully restored sinus rhythm. She presented two more episodes of well-tolerated sustained monomorphic VT treated with lidocaine. Under the diagnosis of electrical storm with three episodes over 8 h, she was transferred to our tertiary referral centre. Ventricular tachycardia. ECG demonstrating a wide QRS complex tachycardia of 220 bpm with right bundle branch block pattern, positive R wave in lead aVR, superior axis, and late transition in lead V6; findings suggestive of ventricular tachycardia. ECG: electrocardiogram. On arrival, another VT episode with the same morphology ceased with procainamide. Esmolol and procainamide infusions were started to prevent further events. Baseline ECG showed sinus tachycardia with a narrow QRS complex, left posterior fascicular block (LPFB), preserved voltages, upright T waves, and no other remarkable feature (Figure 2). An obstetric examination confirmed foetal well-being. Blood tests revealed dilutional anaemia, normal electrolyte values, and rising troponin levels (hs-TnI peak 6477 ng/L, normal range <53 ng/L). A transthoracic echocardiogram (TTE) showed biventricular systolic dysfunction and mild right ventricular (RV) dilation with apical dyskinesia. Despite the significant troponin elevation, coronary angiography was not considered a first-line approach, given the absence of chest pain, cardiovascular risk factors, repolarization abnormalities, or regional wall motion abnormalities suggestive of acute coronary syndrome. Following discussion by the Pregnancy Heart Team, including cardiologists, cardiac intensive care specialists, electrophysiologists, and obstetricians, cardiac magnetic resonance (CMR) was performed for a more precise diagnostic and prognostic assessment. Gadolinium contrast was avoided, considering potential risks to the foetus. CMR demonstrated moderate left ventricular (LV) disfunction (ejection fraction 38%) with high T1 and T2 values in the inferolateral and apical segments and RV impairment (ejection fraction 42%), exhibiting apical free wall dyskinesia (Figure 3). Baseline ECG. Immediate ECG after pharmacological cardioversion of VT showing sinus tachycardia 120 bpm and narrow QRS complex. ECG: electrocardiogram. VT: ventricular tachycardia. Cardiac MRI. T1 mapping (first row) showing an average global value of 1102 ms, markedly higher values in inferolateral region, reaching a maximum 1250 ms at the apical level. T2 mapping (bottom row) revealing high values in the lateral apical region, with a maximum of 75 ms. MRI: magnetic resonance imaging. A diagnosis of biventricular arrhythmogenic cardiomyopathy (ACM) was established following the European Task Force Criteria for ACM.4 She met morpho-functional conditions for both chambers (regional RV dyskinesia with biventricular systolic dysfunction) and electrical ones (sustained VT). Genetic testing later revealed a heterozygous pathogenic desmoplakin (DSP) variant (c.939 + 1G > A), which further supported the diagnosis. Structural criteria could not be established, given that LGE assessment was not feasible. Although ECG did not show classical features of ACM, it demonstrated LPFB and inferior Q waves associated with LV phenotypes.5 The patient’s hospitalization course was favourable. VT ablation was discussed but deferred, given the limited experience in pregnancy and favourable pharmacological response. By day 5, de-escalation from intravenous medication to oral sotalol was allowed, without new arrhythmic events or significant QTc interval prolongation (428 to 439 ms). After electrical stabilization, a transvenous implantable cardioverter-defibrillator (ICD) was recommended, considering the arrhythmic characteristics and potential need for antitachycardia pacing (ATP) therapy. The procedure was performed guided by electroanatomic mapping to minimize foetal radiation (Figure 4). She was discharged after 10 days of hospitalization on sotalol therapy and was advised to avoid moderate- to high-intensity physical activity, despite not having engaged in such activities prior to admission. ICD implantation. Electroanatomic mapping system providing a 3D view of right chambers to guide ICD lead placement. ICD: implantable cardioverter-defibrillator. Early after discharge, two VT episodes terminated by ATP therapy prompted sotalol uptitration. A delivery plan was formulated for scheduled induction at 38 weeks, with planned vaginal delivery under epidural anaesthesia. Continuous ECG monitoring showed no arrhythmic event, and delivery was uncomplicated. After discussing concerns regarding sotalol safety during breastfeeding and therapy modification risks, the patient opted to continue sotalol treatment and formula feeding. She continued outpatient follow-up, and neurohormonal therapy titration was started. She also consented to genetic testing for her children. One year later, she remained asymptomatic (NYHA I), with persistent LV impairment but preserved RV function, and no further sustained arrhythmia. Discussion Pregnancy induces major structural, haemodynamic, and hormonal changes that may precipitate complications in women with underlying CVD.2 It is associated with increased arrhythmic burden and a higher risk of adverse maternal and foetal outcomes.6 Moreover, arrhythmic events are more frequent among pregnant women with pre-existing cardiac conditions, especially cardiomyopathies.7 Available evidence reports that ventricular arrhythmias occur in approximately 5% of pregnancies in women with ACM, without apparent impact on mortality.8 Certain cardiomyopathies can present with episodes resembling myocarditis, sometimes accompanied by malignant arrhythmias. This so-called ‘hot-phase’ phenomenon is characterized by a significant role of inflammation. This pattern has been particularly associated with cases of ACM linked to DSP gene mutations,9 where myocarditis-like episodes occur in approximately 15%–17% of the patients.10,11 In addition to LV dysfunction11,12 and a history of ventricular arrhythmias,12 emerging evidence suggests that variant-specific location may independently contribute to an increased risk of malignant arrhythmias.13 In this case, the c.939+1G>A variant occurs at a critical splice site, leading to abnormal mRNA processing that is predicted to introduce a premature termination codon (p.Gln331*) and is therefore expected to undergo nonsense-mediated decay. Managing CVD during pregnancy requires balancing maternal stabilization and foetal safety and minimizing teratogenic risks. The recommendations of the 2025 ESC guidelines emphasize the role of multidisciplinary Pregnancy Heart Teams in identifying high-risk patients and guiding adequate management. The arrhythmic strategy applied in this case aligns with Section 6 of the guidelines, which addresses cardiomyopathies and primary arrhythmic syndromes. The guidelines support electrical cardioversion as a safe and effective intervention, with a Class I recommendation. When pharmacological therapy is required in arrhythmogenic cardiomyopathy, flecainide, beta-blockers, and sotalol may be considered, with Class IIa/IIb recommendations.14 This case represents the first clinical manifestation of a DSP cardiomyopathy, possibly occurring in the context of the multifactorial physiological stress of pregnancy, including haemodynamic, inflammatory, and hormonal changes that may have contributed to arrhythmogenesis, given the absence of similar arrhythmic episodes outside the gestational period. However, definitive attribution of pregnancy as the trigger cannot be established. Rather than focusing on a pregnancy-associated presentation, this report aims to provide incremental educational value by illustrating the potential inflammatory arrhythmogenic phenotype of DSP cardiomyopathy, characterized in this case by a severe arrhythmic manifestation such as electrical storm, and by discussing the associated diagnostic and therapeutic challenges. In this case, guideline-based management included the use of safe antiarrhythmic agents, avoidance of gadolinium-based contrast in CMR, and minimal-fluoroscopy ICD implantation, with an individualized delivery plan formulated by a multidisciplinary team formulating. In conclusion, pregnancy can precipitate arrhythmias, particularly in patients with underlying CVD. Management remains challenging, and guideline adherence with multidisciplinary care is essential to direct decision-making and ensure maternal and foetal safety. Acknowledgements The authors would like to express their gratitude to both the Departments of Cardiology and Obstetrics for its support during the preparation of this manuscript. We extend special thanks to the Coronary Care Unit staff for their dedicated care of the patient described and to the cardiac imaging unit staff for their invaluable assistance during the diagnostic process, and to the Electrophysiology team for their support in patient management. We are particularly grateful to the patient, who generously consented to share this case for the advancement of medical education. Contributor Information Sara Sóñora-López, Cardiology Department, Vall d’Hebron University Hospital (HUVH), Pg. de la Vall d’Hebron 119, Barcelona 08035, Spain. Víctor González-Fernández, Cardiology Department, Vall d’Hebron University Hospital (HUVH), Pg. de la Vall d’Hebron 119, Barcelona 08035, Spain; Vall d’Hebron Research Institute (VHIR), Pg Vall d'Hebron 129, Horta-Guinardó, Barcelona 08035, Spain; Biomedical Research Networking Centre on Cardiovascular Diseases (CIBERCV), Av. Monforte de Lemos 3-5, Madrid 2809, Spain. Jaume Francisco-Pascual, Cardiology Department, Vall d’Hebron University Hospital (HUVH), Pg. de la Vall d’Hebron 119, Barcelona 08035, Spain; Vall d’Hebron Research Institute (VHIR), Pg Vall d'Hebron 129, Horta-Guinardó, Barcelona 08035, Spain; Biomedical Research Networking Centre on Cardiovascular Diseases (CIBERCV), Av. Monforte de Lemos 3-5, Madrid 2809, Spain; Faculty of Medicine, Autonomous University of Barcelona, Av. de Can Domènech, Bellaterra 08193, Spain. Laura Galian-Gay, Cardiology Department, Vall d’Hebron University Hospital (HUVH), Pg. de la Vall d’Hebron 119, Barcelona 08035, Spain; Vall d’Hebron Research Institute (VHIR), Pg Vall d'Hebron 129, Horta-Guinardó, Barcelona 08035, Spain; Biomedical Research Networking Centre on Cardiovascular Diseases (CIBERCV), Av. Monforte de Lemos 3-5, Madrid 2809, Spain; Faculty of Medicine, Autonomous University of Barcelona, Av. de Can Domènech, Bellaterra 08193, Spain. Antonia Pijuan-Domènech, Cardiology Department, Vall d’Hebron University Hospital (HUVH), Pg. de la Vall d’Hebron 119, Barcelona 08035, Spain; Vall d’Hebron Research Institute (VHIR), Pg Vall d'Hebron 129, Horta-Guinardó, Barcelona 08035, Spain; Biomedical Research Networking Centre on Cardiovascular Diseases (CIBERCV), Av. Monforte de Lemos 3-5, Madrid 2809, Spain; Faculty of Medicine, Autonomous University of Barcelona, Av. de Can Domènech, Bellaterra 08193, Spain. Lead author biography For image description, please refer to the figure legend and surrounding text. Dr. Sara Sóñora López is a medical resident currently completing her Cardiology training at Vall d'Hebron University Hospital. She graduated from University of Santiago de Compostela and has a particular interest in inherited cardiomyopathies, aiming to advance understanding and care for patients with genetic heart conditions. Author contributions Sara Sóñora-López (Conceptualization, Data curation, Methodology, Visualization, Writing—original draft, Writing—review & editing [lead], Investigation [equal]), Víctor González-Fernández (Data curation, Visualization, Writing—review & editing [supporting], Investigation, Supervision, Validation [equal]), Jaume Francisco-Pascual [Data curation, Investigation, Visualization (supporting)], Laura Laura Galián-Gay [Data curation, Investigation, Visualization (supporting)], and Antonia Pijuan-Domènech (Investigation, Writing—review & editing [supporting], Supervision, Validation [equal]) Consent: Written informed consent was obtained from the patient for publication of the case details and accompanying images. This report has been prepared in accordance with the ethical standards of the journal and complies with the guidelines of the Committee on Publication Ethics (COPE). All information has been anonymized, and every effort has been made to ensure patient confidentiality. Funding The authors report there has not been funding. Data availability The data underlying this article are not publicly available due to patient confidentiality. References Associated Data Data Availability Statement The data underlying this article are not publicly available due to patient confidentiality.